Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1HER-2 Positive Advanced Gastric Cancer 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 41Paclitaxel 32Radiotherapy 28Cisplatin 25Bevacizumab 24Erlotinib Hydrochloride 19Pemetrexed 18Docetaxel 16Gemcitabine 15Gefitinib 8Vinorelbine 7Taxes 7Cetuximab 7ceritinib 5Surgical Procedures, Operative 5Etoposide 5Amplified Fragment Length Polymorphism Analysis 5sargramostim 3pembrolizumab 3capmatinib 3Radiotherapy, Conformal 3Radiation 3Gene Expression Profiling 3Cyclophosphamide 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2pegfilgrastim 2osimertinib 2Topotecan 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of Lung × HM781-36B × Clear all
NCT02979821 2018-05-24

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Korean Association for the Study of Targeted Therapy

Phase 2 Completed
6 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡